Sweden: Engineering Nouryon to Expand Manufacturing Unit in Bohus
With an aim to meet the global pharma and biotech demand, Nouryon has plans to expand its Kromasil manufacturing facility in Bohus, Sweden. The move is expected to support the company’s global leadership position in high-performance silica.
Amsterdam/The Netherlands – Nouryon has plans to invest in its Kromasil manufacturing facility in Bohus, Sweden, to meet the increasing global demand from the pharmaceutical and biotechnology industries for high-performing solutions. The investment is expected to double the facility’s existing production capacity, which will strengthen Nouryon’s global leadership position in high-performance silica.
Kromasil products are used by the pharmaceutical, food and beverage, clinical, and environmental industries for applications ranging from laboratory analysis to industrial-scale purification. Kromasil contributes to improved treatment of diabetes as a vital part of the purification of insulin. Other uses include complex bio-pharma applications.
This facility expansion will reinforce our leadership position in the global high-performance silica market targeted to the pharma and biotech industries, and it will allow us to meet the growing demand for our Kromasil products.
“Bio-pharmaceuticals, such as peptides, proteins and hormones, are a growing market and we see an increase in demand worldwide, particularly from our customers in India, China and Southeast Asia,” said Patrick Wilhelm, Vice President of Inorganic Specialties at Nouryon.
Construction of the Nouryon facility expansion is scheduled to begin in 2022.